Huskeys, which uses agentic AI to help companies block AI-driven attacks, raised a $27M Series A led by Blackstone Innovations Investments at a $100M+ valuation
THE SO WHAT
A $27M Series A at a $100M+ valuation for Huskeys is a bet that AI-native defense will be its own category, not just a feature in legacy tools. Security teams should start asking vendors how they detect and mitigate automated AI-driven traffic specifically, not just generic bots.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureAm I a fake founder? What it’s like joining a startup as a cofounder a year late
Late-stage cofounders are increasingly a structural tool — a way to bolt on missing skills, credibility, or networks once the company has real signal. If you’re an early team or investor, be explicit in paper and in culture about what ‘founder’ means, or you’ll store up resentment and misaligned expectations for the first real stress event.
Startups & VentureExclusive: Legaltech Lexroom seals first two M&A deals four months after $50m Series B
Lexroom moving to M&A just four months after a $50m Series B says legaltech is consolidating into platforms, not point tools. If you’re building or buying in this category, underwrite against roll-up dynamics — either become an acquirer or design your product and contracts to be an easy plug-in for one.
Startups & VentureFirmus to Start Investor Meetings for Australia IPO, AFR Says
Firmus kicking off investor meetings for an Australian IPO is another data point that public markets are reopening selectively for tech. If you’re a late-stage company in that region, treat this as a pricing test — watch valuation multiples and demand quality before you lock in your own timing.
Startups & VentureAnthropic Said to Walk Away From $6 Billion Decart Acquisition
Walking away from a reported $6B deal is a reminder that top labs are still selective about inorganic bets — talent and IP are abundant enough that overpaying for one startup is optional. If you’re building in the AI tooling or infra layer, assume partnership and distribution deals may be more realistic than a near-term lab acquisition.